Senti bio to present updated clinical results of first-in-class logic gated cd33/flt3 cell therapy, senti-202, at the american society of hematology (ash) annual meeting 2025

South san francisco, calif., nov. 03, 2025 (globe newswire) -- senti biosciences, inc. (nasdaq: snti) (“senti bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that it will deliver two presentations, including one oral, on its senti-202 clinical program, at the 67th american society of hematology (ash) annual meeting and exposition being held december 6-9, 2025 in orlando, florida. senti bio will also host a live webcast to discuss the latest data during the annual meeting.
ASH Ratings Summary
ASH Quant Ranking